ClinicalTrials.gov
public full text
Public Domain
Soluble CD23 Expression in Asthma Patients Treated With OMA
This study involves a FDA approved drug, Omalizumab, used in the treatment of moderate to severe allergic asthma that cannot be controlled by standard treatment. It works on IgE to control the allergic reaction. We are looking at the effects on non-allergic asthma. We hope to prove that Omalizumab will have the same effect on non-allergic asthmatics as it does allergic asthmatics.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effect of Anti-IgE in Non-Allergic Asthma#1030347
- Inner-City Anti-IgE Therapy for Asthma#806090
- The Effect of Xolair (Omalizumab) on Allergy Blood Cells#1044352
- Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma#1059889
- Educational Intervention for Asthmatic and Allergic Patients#1073488
Record · ID 849103
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive